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Epstein–Barr virus (EBV) latent membrane protein (LMP)-1 induces B lymphocyte immortalization and activates constitutive
signal transduction, including NF-B, JNK/p38, and JAK/STAT pathways. During EBV latency, LMP-1 expression induces
several B lymphocyte activation markers, including intercellular adhesion molecule (ICAM)-1. We found that various struc-
turally distinct histone deacetylase inhibitors (HDACI), as well as phorbol ester treatment, induced homotypic aggregation in
EBV-positive Burkitt’s lymphoma lines. Cell-surface expression of ICAM-1 was concurrently strongly up-regulated by both
HDACI and phorbol ester treatments. Cell-surface expression of ICAM-1 was concurrently strongly induced by both HDACI
and phorbol ester treatment. Among several ICAM family members, only ICAM-1 was up-regulated by both HDACI and
phorbol ester treatments, suggesting that up-regulated ICAM-1 expression might mediate the observed increase in
homotypic aggregation. HDACI-induced homotypic aggregation was blocked by exposure to a monoclonal antibody specific
for the -chain (CD18) of an ICAM-1 ligand, LFA-1. Unexpectedly, HDAC inhibition, but not phorbol ester treatment, induced
LMP-1 expression in EBV-positive cell lines, and this LMP-1 species was identified by RT-PCR and immunoblot analyses as
the latent form of LMP-1. Control of EBV LMP-1 gene expression by HDACI inhibition occurs at the transcriptional level, as
indicated by nuclear runoff studies and analysis of steady-state mRNA levels. Dominant-negative LMP-1 efficiently blocked
HDACI-induced ICAM-1 up-regulation, and ectopic expression of LMP-1 activated expression of an ICAM-1 promoter-driven
reporter gene. The HDACI-induced up-regulation of ICAM-1, and consequent homotypic aggregation, were efficiently blocked
by the addition of N-acetyl-L-cysteine and by ectopic expression of a super-repressor IB, while LPM-1 induction was
unaffected, suggesting that these effects are mediated by NF-B. We demonstrate, therefore, that the latent isoform of LMP-1
is induced by HDAC inhibition, and that HDACI-induced latent LMP-1 expression, through NF-B activation, is responsible forINTRODUCTION
Epstein–Barr virus (EBV, human herpesvirus type 4),
first described in 1964, is an extensively studied lym-
phocryptovirus in the -type herpes virus family, and a
common pathogenic human DNA virus. The gamma her-
pes viruses establish latent infection in lymphocytes and
are associated with cell proliferation, and, in some
cases, transformation and cancer. EBV is a causative
etiologic agent for a variety of human diseases, including
endemic Burkitt’s lymphoma, posttransplantation lym-
phoproliferative disease, undifferentiated nasopharyn-
geal carcinoma, and infectious mononucleosis (Adams,
1980; Baer et al., 1984; Cohen, 2000; de-The´, 1980; Kieff,
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the epithelial cells of the oropharynx. The outcomes of B
lymphocyte infection can include latent infection, imme-
diate entry of infected cells into the cell cycle, immortal-
ization, and/or transformation. In its latent state, the ep-
isomal EBV genome expresses a limited number of
genes, including EBERs (small nonpolyadenylated
RNAs), EBNAs (nuclear antigens), and LMPs (latency
integral membrane proteins). Depending on EBNA and
LMP expression patterns, latency can be classified into
one of three different states (Rowe et al., 1987; Zetterberg
et al., 1999).
Among the latency proteins, EBNA-1, -2, and LMP-1
are critical B lymphocyte transformation factors (Cohen
et al., 1989; Cohen, 1997; Rowe, 1999; Young et al., 2000).
LMP-1 acts as an oncoprotein in certain cell lines, as
exogenous expression of LMP-1 in rodent fibroblasts in
vitro causes transformation (Wang et al., 1985). EBNA-2
is a strong activator of LMP-1 expression in EBV latencyICAM-1 expression up-regulation and homotypic adhesion
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blom et al., 1998). LMP-1 up-regulates anti-apoptotic pro-
teins, including Bcl-2, A20, Mcl-1, and Bfl-1, and these
contribute to its oncogenic potential (Brennan et al.,
2001). LMP-1 also up-regulates B cell activation markers,
including CD21, CD23, CD71, CD54, and TAP-1/-2, a com-
ponent of the endogenous antigen processing pathway
(Liljeholm et al., 1998; Young et al., 2000; Zhang and
Pagano, 2001). LMP-1 is a 63-kDa protein composed of
three domains. The function of short cytosolic N-terminal
remains unclear. The six transmembrane domains are
required for LMP-1 aggregation on cellular membrane
and for signal transduction. The long cytosolic C-terminal
domain of 200 amino acids contains the C-terminal ac-
tivating regions (CTAR) -1 and -2, which are essential for
LMP-1-mediated transformation, and the activation of
NF-B mediated by these regions is implicated in LMP-
1-mediated cell immortalization (Huen et al., 1995). The
CTAR-2 domain was recently found to induce the JNK/
p38 pathway (Eliopoulos and Rickinson, 1998; Eliopoulos
et al., 1999a,b; Faller et al., 2001; Kieser et al., 1997;
Leibowitz, 1998). In addition, the region between CTAR-1
and -2 (CTAR-3) is known to induce the JAK/STAT path-
way (Gires et al., 1999). Thus, LMP-1 mimics a constitu-
tively active tumor necrosis factor receptor (TNF-R), and
this constitutive activity culminates in cell immortaliza-
tion and transformation (Kilger et al., 1998).
Intercellular adhesion molecule (ICAM)-1 (CD54) is a B
lymphocyte activation marker known to be involved in
homotypic aggregation, particularly in type III lympho-
blastoid cell lines (LCL) (Rothlein and Springer, 1986).
ICAM-1 is a member of the immunoglobulin (Ig) super-
family of cellular adhesion molecules (CAMs). Many in-
flammatory stimuli regulate cell–cell interactions through
expression of ICAM-1. While basal levels of ICAM-1 ex-
pression are usually low, activation by tumor necrosis
factor- (TNF-), lipopolysaccharide (LPS), interleukin 1
(IL-1), or interferon- up-regulate ICAM-1 expression on
the surface of cell types of diverse origins, including
myeloid, fibroblastic, epithelial, and endothelial cell
types (Collins et al., 1995; Jahnke and Johnson, 1995;
Ledebur and Parks, 1995; Stratowa and Audette, 1995;
Wertheimer et al., 1992). LFA-1, an integrin superfamily
member, is a counterreceptor for all of the ICAMs
(Sanchez-Madrid et al., 1983). The interaction affinity of
ICAM-1 to LFA-1 is the strongest among these interac-
tions. In the EBV-positive type III LCL line JY, an ICAM-
1/LFA-1 interaction was shown to mediate the homotypic
aggregation induced by phorbol ester treatment. Block-
ing mAbs against LFA-1 inhibits or delays the aggregate
formation in phorbol ester treated JY cells (Rothlein and
Springer, 1986).
Histone acetylation and deacetylation are critical mod-
ulators in the regulation of expression of many genes
(Archer and Hodin, 1999; Hassig and Schreiber, 1997;
Pazin and Kadonaga, 1997; Roth and Allis, 1996; Struhl,
1998; Wade and Wolffe, 1997). In addition, altered histone
acetylase (HAT) and deacetylase (HDAC) activities are
implicated in the development or progression of cancers
(Marks et al., 2000). Histone deacetylase inhibitors (HDA-
CIs), by altering the chromatin structure adjacent to gene
promoters, can deregulate gene expression. Among sev-
eral known HDACI agents, butyrate has long been used
to reactivate EBV from latency, usually in conjunction
with phorbol ester (Anisimova´ et al., 1982, 1984; Collan-
dre et al., 1984; Kawanishi and Ito, 1980; Kawanishi et al.,
1981, 1983; Miller, 1989; Shadan et al., 1994; Sugawara et
al., 1982; Weigel and Miller, 1983). Histone acetylation/
deacetylation regulates EBV immediate-early gene ex-
pression, particularly that of Zta and Rta (Chang and Liu,
2000; Jenkins et al., 2000). HDACI exposure results in
acetylation of histones surrounding the Zta and Rta pro-
moters, inducing transcription of these genes. Once in-
duced, Zta causes cell-cycle arrest in G1 phase and
transactivates the early lytic genes, ultimately inducing
the entire lytic process (Rodriguez et al., 1999). HDAC
inhibition does not induce the EBV reactivation process
in all EBV-positive Burkitt’s lymphoma (BL) cell lines,
however, demonstrating that the EBV reactivation pro-
cess by chromatin modulation is cell type dependent. We
report here that the EBV reactivation process in a num-
ber of BL lines is readily induced by butyrate or other
HDACIs alone, and, among several different EBV-positive
BL lines studied, P3HR-1 was the most responsive to
HDACI. P3HR-1 contains an EBV genome with a well-
characterized deletion in the EBNA-2 and EBNA-LP re-
gion. These deleted genes are normally thought to be
critical for immortalization of B lymphocytes and for
LMP-1 activation. The P3HR-1 line grows in small clumps
during culture, consistent with type II/III type latency
(Zetterberg et al., 1999). Exposure to any of a variety of
HDACIs resulted in massive homotypic aggregation, in-
duction of ICAM-1 expression, and concurrent partial
reactivation from latency. We found that HDACI-stimu-
lated induction of “latent” LMP-1 is responsible for
ICAM-1 up-regulation and the observed homotypic ag-
gregation.
RESULTS
Histone deacetylase inhibitors induce homotypic
aggregation in EBV-positive Burkitt’s lymphoma cell
lines
Phorbol esters are known to induce homotypic aggre-
gation in certain EBV-immortalized lymphoblastoid B cell
lines (Rothlein and Springer, 1986). Phorbol esters are
also potent viral reactivating agents for cells containing a
latent EBV genome and are often used in combination
with butyrate for full reactivation of the EBV lytic process
in EBV-positive BL cell lines, such as P3HR-1 (Kawanishi
and Ito, 1980; Kawanishi et al., 1983). More recently,
butyrate or other HDACIs alone have been shown to
induce EBV reactivation to some extent (Jenkins et al.,
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2000). We found that phorbol ester treatment induced
homotypic aggregation in the P3HR-1 cell line within
24 h, as previously reported (Fig. 1). Exposure to butyrate
or trichostatin A (a structurally distinct HDACI) induced
comparable aggregation, in a similar time frame. When
the EBV-negative Ramos line was studied under similar
conditions, however, only phorbol ester treatment in-
duced aggregation, whereas exposure of the Ramos line
to HDACIs did not induce any observable homotypic
aggregation. Butyrate was used at a lower final concen-
tration in Ramos cells (1.0 mM) than in P3HR1 cells (2.5
mM), because higher concentrations were toxic in the
Ramos cell line. HDACI or phorbol ester treatment also
induced homotypic aggregation in another EBV-positive
BL line, Daudi (unpublished data, Park and Faller). Be-
cause HDACIs induced homotypic aggregation in the
EBV-positive P3HR-1 and Daudi lines, but not in the
EBV-negative Ramos line, these results suggested that
the presence of EBV, and presumably gene product(s) of
EBV, might be involved in HDACI-induced homotypic ag-
gregation, whereas phorbol ester treatment could induce
a distinct, EBV-independent mechanism for aggregation
common to all B cell types.
A monoclonal antibody (mAb) directed against
the common 2 chain (CD18) of LFA-1 inhibits
HDACI-induced homotypic aggregation
Homotypic aggregation in EBV-positive BL cell lines is
mediated through the interaction of the intercellular ad-
hesion molecules (particularly ICAM-1) and leukocyte
function-associated antigen (LFA)-1, an integrin family
cellular adhesion molecule (Makgoba et al., 1988; Roth-
lein and Springer, 1986). To determine whether such an
ICAM/LFA-1 interaction was responsible for the homo-
typic aggregation induced by HDACIs or phorbol ester,
we attempted to block this interaction by specific mono-
clonal antibodies. The LFA-1 molecule is composed of -
and -chains (specifically L and 2) (Binnerts and van
Kooyk, 1999). The mAb TS1/18, which is specific to the 2
(CD18) chain, is known to block adhesive interactions
between ICAM-1 and LFA-1 (Rothlein and Springer,
1986). The TS1/18 mAb completely blocked HDACI-in-
duced, and phorbol ester-induced, homotypic aggrega-
tion in the P3HR-1 line (Fig. 2A). As a control, the TS1/18
mAb also blocked phorbol ester-induced homotypic ag-
gregation in the EBV-positive LCL line JY, as previously
reported (Fig. 2A) (Mentzer et al., 1986a,b; Rothlein and
Springer, 1986). The W6/32 mAb, an isotype-matched
mAb directed against a framework antigen in human
MHC class I (HLA-A, -B, and -C), had no effect on homo-
typic aggregation of P3HR1 or JY. The P3HR-1 line was
positive for both CD18 and MHC class I expression on
the cell surface, as determined by flow cytometric anal-
ysis, and the antigen densities were not up-regulated by
butyrate or phorbol ester treatments (Fig. 2B). The results
from the LFA-1 blocking studies suggested that an inter-
action between ICAMs and LFA-1 might be responsible
for the observed homotypic aggregation induced by
HDACI or phorbol ester treatment. Attempts to confirm
these experiments using a blocking antibody directed
against ICAM-1 were confounded by the finding that the
anti-ICAM mAb alone increased spontaneous aggrega-
tion in all EBV-positive B cell lines tested, in an isotype-
specific fashion (unpublished data, Park and Faller).
Histone deacetylase inhibition up-regulates
intercellular adhesion molecule (ICAM)-1 expression
in EBV-positive cell lines
The LFA-1 antibody-blocking studies detailed above
suggested that an ICAM/LFA-1 interaction was respon-
sible for the homotypic aggregation induced by HDACI or
phorbol ester treatments. To determine which ICAM mol-
ecule is involved in HDACI- or phorbol ester-induced
homotypic aggregation, we examined ICAM and LFA-1
cell surface expression levels in HDACI- or phorbol es-
ter-treated P3HR-1 and Ramos cell lines using flow cy-
tometry. The EBV-positive P3HR-1 cell line expressed
moderate levels of ICAM-1, -2, and LFA-1 (CD11a and
CD18 antigens) under basal (control) conditions (Fig. 3A).
In contrast to the P3HR-1 line, EBV-negative Ramos cells
expressed moderate levels of ICAM-1, -2, and -3, but no
LFA-1 under the same conditions (Fig. 3B). Upon treat-
ment of the P3HR-1 line with either of two HDACIs
(butyrate or trichostatin A (TSA)), the density of cell-
surface ICAM-1 antigen was significantly increased,
ranging from 5- to 10-fold (depending on length of expo-
sure, data not shown), without any significant changes in
ICAM-2, -3, or LFA-1 expression levels. ICAM-1 expres-
sion on the P3HR-1 line also increased significantly after
stimulation with phorbol ester for 48 h, and LFA-1 (CD11a
and CD18) expression levels were slightly increased with
phorbol ester treatment. In Ramos cells, however, HDACI
FIG. 1. HDACI and phorbol ester treatments induce homotypic ag-
gregation in P3HR-1 line. P3HR-1 and Ramos cells were plated as 5 
106 cells in 10 ml RPMI complete growth medium. Butyrate, at final
concentrations of 2.5 or 1.0 mM, was added to the P3HR-1 and Ramos
lines, respectively. TSA or PMA was added to final concentrations of
100 and 20 ng/ml, respectively. The cells were incubated for 24 h and
examined under phase contrast microscopy, and representative fields
were photographed.
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or phorbol ester treatment did not change the level of
expression of ICAM-1, -2, -3, or LFA-1. To confirm up-
regulation of ICAM-1 protein expression in P3HR-1 cells
by HDACI or phorbol ester treatment, immunoblot anal-
ysis of total cell lysates was carried out, using a human
ICAM-1-specific mAb. Total cellular ICAM-1 levels were
up-regulated approximately 10-fold by exposure to HDAC
inhibitors (butyrate, trichostatin A, or suberohydroxamic
acid (SHA), another HDAC inhibitor which is structurally
similar to trichostatin A) and up-regulated sixfold by
phorbol ester treatment in the P3HR-1 cell line. In con-
trast, total cellular levels of ICAM-1 were not altered
significantly in HDACI- or phorbol ester-treated Ramos
cells (Fig. 4). It is noteworthy that phorbol ester treatment
of the Ramos line induced homotypic aggregation (see
Fig. 1), despite the absence of LFA-1 (CD11a/CD18) ex-
pression and without any change in levels of ICAM-1, -2,
or -3 expression (Fig. 3B). These results suggest that
phorbol ester-mediated homotypic aggregation differs
mechanistically from HDACI-induced homotypic aggre-
gation. Furthermore, it is likely that a gene product of
EBV is necessary for, or mediates, induction of ICAM-1
expression in B cell lines in response to HDACI treat-
ment, because this induction occurred only in EBV-pos-
FIG. 2. Effect of anti-CD18 mAb treatments on HDACI- and phorbol ester-induced homotypic aggregation. (A) P3HR-1 and JY cells were treated with
butyrate (2.5 mM), TSA (100 ng/ml), SHA (60 M), or phorbol ester (20 ng/ml) for 24 h before harvesting. Cells were resuspended in fresh medium
at 106 cell/ml and 50 l of cell suspensions were replated into 96-well plates. One hundred microliters of each mAb supernatant was added to the
appropriate wells and the cells were further incubated for 12 h before photographing them. (B) Butyrate (2.5 mM) or phorbol ester (20 ng/ml) treated
P3HR-1 cells were harvested and stained with TS1/18 or W6/32 mAbs, as described under Materials and Methods. FITC-conjugated goat antimurine
mAb was used as the secondary Ab and cells were detected in the FL1 channel by flow cytometric analysis. The (control) profiles depicted by the
thin lines were generated from cells treated with second antibody alone.
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itive cell lines (e.g., P3HR-1 and Daudi lines), and not in
EBV-negative lines (such as Ramos).
Exogenous expression of LMP-1 induces ICAM-1
expression
Exposure to two structurally distinct HDACIs induced
ICAM-1 expression in the P3HR-1 cell line, and this effect
appeared to be dependent upon the presence of the EBV
genome. HDACIs (specifically butyrate), alone or in com-
bination with phorbol esters, are known to induce reac-
tivation of latent EBV in numerous LCL and tumor cell
lines (Anisimova´ et al., 1982, 1984; Kawanishi and Ito,
1980; Miller, 1989). We have shown that exposure to
butyrate or other HDACIs (trichostatin A and suberoylhy-
droxamic acid) as single agents can induce robust par-
tial reactivation in the P3HR-1 line within 6 h, as as-
sessed by induction of immediate-early genes (BZLF1
and BRLF1), early genes (thymidine kinase), and late
genes (BALF4, encoding gp110) (unpublished data, Park
and Faller). Interestingly, phorbol ester treatment alone
FIG. 3. Flow cytometric analyses of ICAM and LFA-1 antigens on HDACI- or phorbol ester-treated P3HR-1 and Ramos lines. 5  106 cells of the
P3HR-1 (A) or Ramos (B) lines were treated with each drug for 24 h, harvested, and antibody-stained for cell-surface expression of CD11a, CD18, and
ICAM-1/-2/-3, as described under Materials and Methods. Butyrate was used at a final concentration of 2.5 mM (P3HR1) or 1 mM (Ramos). TSA or
PMA was used at final concentrations of 100 or 20 ng/ml, respectively. Antibody-stained cells were analyzed in the FL1 channel. The (control) profiles
depicted by the thin lines were generated from cells treated with second antibody alone.
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did not induce the expression of the EBV immediate-
early gene encoding Zta and Rta until 48 h. Zta and Rta
are the protein products of the immediate early genes
BZLF1 and BRLF1, respectively, and are transcriptional
transactivators. Because HDACI induced EBV immedi-
ate-early gene expression rapidly (6 h), the time course
was consistent with the possibility that the transactivat-
ing protein encoded by one of these immediate-early
genes might be responsible for the induction of ICAM-1
expression. Transfections with Zta and Rta expression
vectors, together with an E-GFP vector to allow identifi-
cation of transiently transfected cells, were carried out to
determine whether either of these immediate early gene
products could induce ICAM-1 expression in an EBV-
negative B cell line, Ramos. Ectopic Zta or Rta expres-
sion did not up-regulate ICAM-1 expression levels in the
strongly expressing GFP-positive gated population (Fig.
5A). The EBV LMP-1 was recently recognized as an
activator of ICAM-1 expression during EBV latency (Kieff,
1996; Liljeholm et al., 1998; Mehl et al., 2001). We dem-
onstrated that ectopic expression of LMP-1, by transfec-
tion of an LMP-1 expression vector into the Ramos and
P3HR-1 lines, up-regulated the levels of ICAM-1 expres-
sion in both Ramos and P3HR-1 GFP-positive gated
transfectants by a factor of 4. Expression of transfected
Zta/Rta and LMP-1 were verified by activation of specific
responsive reporter vectors (pSSB-luc and pICAM-1p-luc
[BglII], respectively) (Fig. 5B).
EBV LMP-1 is induced by HDACI
We next determined whether HDACI or phorbol ester
treatment induced endogenous LMP-1 transcripts in the
P3HR-1 cell line. Somewhat surprisingly, LMP-1 tran-
script (2.5 kb) levels, which were undetectable prior to
treatment, were strongly induced by exposure to HDA-
CIs, but not to phorbol ester (Fig. 6A). A smaller transcript
(0.8 kb) was also induced in a parallel fashion and has
been reported as a late transcript from the BamHI N
fragment (Hudson et al., 1985). LMP-1 has been charac-
terized as a latent protein in EBV life cycle, whereas
HDAC inhibition (in combination with phorbol esters) is
known to terminate latency and induce the EBV reacti-
vation process. A “lytic” form of LMP-1, which is induced
during EBV reactivation process, has been described
(Contreras-Salazar et al., 1990; Erickson and Martin,
2000; Hudson et al., 1985). To determine whether the lytic
or latent form of LMP-1 was being induced by HDAC
inhibition, we designed a specific RT-PCR primer set to
identify the latent LMP-1 isoform only. Latent and lytic
forms share a third exon that encodes the fifth and sixth
transmembrane domains and full C-terminal domain of
LMP-1 protein. The lytic form of LMP-1, however, does
not contain the first and second exons (Hudson et al.,
1985). Based on these differences, we chose a sense
primer from first exon and an antisense primer from third
exon, enabling us to detect only the latent LMP-1 tran-
script. Transcripts for the latent isoform of LMP-1 were
clearly induced by HDACI treatment, but not by phorbol
ester treatment (Fig. 6B). To confirm that the induction of
the latent LMP-1 transcript resulted in a concomitant
increase in latent LMP-1 protein levels, immunoblot anal-
ysis was carried out, employing an LMP-1-specific mAb
(CS1-4, which recognizes both latent and lytic forms of
LMP-1). Consistent with the results from the RNA blot
and RT-PCR analyses, the expression of the latent iso-
form of LMP-1 protein was strongly induced, from initially
undetectable levels, by each of three distinct HDACIs
(butyrate, TSA, and SHA), but not by phorbol ester treat-
ment in the P3HR-1 line (Fig. 6C). None of the lytic
isoform of LMP-1 (approximately 45 kDa) was detected,
either before or after HDAC inhibition (not shown) (Erick-
son and Martin, 2000). Thus, HDACI induces latent-iso-
form LMP-1 expression in the course of EBV reactivation
in the P3HR-1 cell line.
HDAC inhibition induces EBV LMP-1 gene expression
at the transcriptional level
To determine whether the induction of LMP-1 by
HDACI during EBV reactivation process reflected differ-
ences in the transcription rate of the LMP-1 gene, nu-
clear runoff experiments were performed. Nuclei were
isolated from control, butyrate-, TSA-, and phorbol ester
(PMA)-treated P3HR-1 cells, and transcription was then
allowed to proceed in the presence of 32P-labeled UTP.
-actin-specific, EBV thymidine kinase (TK)-specific, and
EBV LMP-1-specific transcripts were detected after ex-
haustive hybridization to homologous sequences. pGEM
and -actin DNA sequences were included as negative
and positive internal controls, respectively. The EBV TK
gene was included as a positive control for EBV reacti-
vation. The EBV LMP-1 transcription rate was increased
by butyrate or TSA treatment, by 2.7- and 2.2-fold, respec-
FIG. 4. Immunoblot analysis of human ICAM-1 expression in HDACI
or phorbol ester treated P3HR-1 and Ramos lines. Thirty micrograms of
protein from total cell lysates of cells treated as described in the legend
to Fig. 3 was separated in each lane, using 10% SDS–PAGE. The
separated proteins were transferred to nitrocellulose membranes. Hu-
man ICAM-1 protein was detected using the G-5 mAb, peroxidase-
conjugated anti-murine IgG, and ECL Plus Western Blotting Detection
Reagents, and captured on film. C, B, T, S, and P stand for control,
butyrate, TSA, SHA, and PMA, respectively.
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tively, compared to control, by densitometric analysis
(Fig. 7). The EBV TK transcription rate was also in-
creased, as expected. Thus, the increased levels of
LMP-1 mRNA induced by HDAC inhibition are chiefly or
solely attributable to effects at the transcriptional level.
Expression of a dominant-negative LMP-1 blocks
induction of ICAM-1 expression by HDAC inhibition
LMP-1 has oncogenic activity in a number of experi-
mental systems and can induce several B cell activation
markers, including ICAM-1 (Kulwichit et al., 1998; Wang
et al., 1985). While the exact mechanism of LMP-1-medi-
ated ICAM-1 expression up-regulation is still not clear,
the activation of the transcription factor NF-B by LMP-1
appears necessary for this induction (Devergne et al.,
1998; Eliopoulos et al., 1999a,b; Huen et al., 1995, Izumi
and Kieff, 1997; Izumi et al., 1999; Kieser et al., 1997, 1999;
Mehl et al., 2001; Sylla et al., 1998). A number of other
transcriptional inducers of ICAM-1 also function through
NF-B (Collins et al., 1995; Jahnke and Johnson, 1995;
Wertheimer et al., 1992). The C-terminal activation re-
gions -1 and -2 of LMP-1 (CTAR-1 and -2) have recently
been shown to induce NF-B activation through binding
of TRAF2 and TRADD, respectively (Devergne et al., 1998;
Eliopoulos et al., 1999b; Izumi and Kieff, 1997; Izumi et al.,
1999; Kieser et al., 1999; Sylla et al., 1998). The substitu-
tion of the critical Pro204/Gln206/Thr208 residues in the
LMP-1 CTAR-1 domain to Ala abolished TRAF binding,
and ultimately NF-B activation, by LMP-1. Similarly, the
substitution of the Tyr384 residue to Gly in the CTAR-2
domain abolished TRADD binding and the activation of
NF-B and AP-1 by LMP-1. An LMP-1 mutant containing
FIG. 5. Transient transfection of the EBV immediate-early gene products Zta and Rta, and LMP-1, and effects on ICAM-1 expression. (A) 1  107
Ramos cells were cotransfected with a total of 30 g of DNA (10 g of E-GFP plus 20 g of each expression vector or empty control vector) by
electroporation. In the transfections of LMP-1, P3HR-1 cells were transfected as well. After 48 h, transfectants were harvested and cell surface stained
with a human ICAM-1 mAb and phycoerythrin (PE)-conjugated anti-murine IgG Ab. The strongly GFP-positive cell population in the FL1 channel was
gated on and analyzed for ICAM-1 expression level in the FL2 channel. The (control) profiles depicted by the thin lines were generated from cells
treated with second antibody alone. (B) The pSSB-luc or pICAM-1p-luc (BglII) reporter constructs were cotransfected into the P3HR-1 cell line with
Zta, Rta, Zta/Rta, or LMP-1 expression vectors. The pSV2-luc vector was used as a transfection positive control. A total of 20 g DNA (normalized with
pGEM or pSG5 vector) was used in each transfection. Luciferase reporter activity was measured and expressed as specific activity (U/mg protein).
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all of these substitutions (LMP-1AAAG) has been shown to
act as a dominant-negative protein and also prevented
activation of the JAK/STAT signaling pathway by LMP-1
(Brennan et al., 2001). We utilized this dominant-negative
LMP-1AAAG to determine whether it would block ICAM-1
up-regulation by HDACI. In cotransfection experiments
with E-GFP (to facilitate identification of transiently trans-
fected cells), LMP-1AAAG efficiently blocked HDACI-in-
duced ICAM-1 up-regulation in the GFP-positive gated
population by 41% compared to control (Fig. 8A and Table
1). In parallel studies, ICAM-1 promoter-luciferase re-
porter vectors (pICAM-1p-luc) were cotransfected with
wild-type and/or dominant-negative LMP-1 expression
vectors to examine transcriptional regulation of the
ICAM-1 promoter. Vectors containing luciferase genes
driven by a well-characterized, responsive human
ICAM-1 promoter element (extending to a BglII site
1150 bp upstream from the start site) or a minimal
ICAM-1 promoter element (extending to an NheI site60
bp upstream from the start site) were used. ICAM-1
promoter activity was up-regulated 2.8-fold by expres-
sion of wild-type LMP-1, and this induction was inhibited
by the coexpression of the dominant-negative LMP-1
vector, demonstrating that LMP-1 expression is sufficient
for the observed ICAM-1 expression up-regulation and
that the DN-LMP-1AAAG construct was expressed and
functional (Fig. 8B). Collectively, these findings demon-
strate that HDAC inhibition induces ICAM-1 up-regula-
tion through induction of latent LMP-1, which then likely
acts through NF-B activation.
Inhibition of NF-B activation abolishes
HDACI-induced up-regulation of ICAM-1
expression and homotypic aggregation
Latent LMP-1 is thought to mediate ICAM-1 up-regu-
lation through NF-B activation via its CTAR-1 and -2
domains. In the normal course of NF-B activation by
FIG. 6. Effect of HDACI or phorbol ester treatment on EBV LMP-1 transcript and protein levels. (A) Total RNA was prepared from drug-treated (2.5
mM butyrate, 100 ng TSA/ml, 60 M SHA, or 20 ng PMA/ml) or untreated cells. Twenty micrograms of total RNA was separated in each lane on a
1% formaldehyde-agarose gel, stained with ethidium bromide, denatured, transferred to a nitrocellulose membrane in 20 SSC buffer, and
photographed under ultraviolet illumination to confirm equal loading (bottom). The membrane was hybridized with a 32P-labeled LMP-1-specific cDNA
sequence. After stringent washing, the membrane was subjected to autoradiography. The migration positions of the 28S and 18S rRNA species are
indicated. (B) Total cellular RNA was incubated with RNase-free DNase, and 5 g of RNA was used for each RT-PCR reaction. A lytic LMP-1-specific
RT-PCR primer set was constructed, based on exon 1 and exon 3 sequences of EBV LMP-1. A -actin primer set was also used as an internal control.
The PCR products were analyzed on a 1% agarose gel and shown here after staining with ethidium bromide. (C) P3HR-1 cells were treated with
HDACIs or PMA, as indicated above. For detection of LMP-1 protein, 30 g of total cell lysate protein was separated in each lane on 10% SDS–PAGE,
transferred to nitrocellulose, and immunoblotted with an EBV LMP-1 mAb (CS1-4). The migration positions of molecular mass markers are shown on
the left. The migration position of the approximately 60 kDa latent LMP-1 protein is indicated. Lysates from Ramos cells were run in parallel as a
negative control. C, B, T, S, and P stand for control, butyrate, TSA, SHA, and PMA, respectively.
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effectors such as phorbol esters or TNF, the degradation
of IB by the ubiquitin/proteasome pathway ultimately
allows translocation and activation of the NF-B com-
plex. To demonstrate that NF-B activation is required for
the observed up-regulation of ICAM-1, we used the re-
ducing agent and proteasome inhibitor, N-acetyl-L-cys-
teine (NAC) to inhibit activation of NF-B. Treatment of
P3HR-1 cells with NAC effectively inhibited the ICAM-1
up-regulation induced by three discrete HDACI (butyrate,
TSA, and SHA) and by phorbol esters, by 67–100% (Fig.
9A and Table 1). Treatment of the Ramos line with NAC
also completely inhibited phorbol ester-induced ICAM-1
up-regulation (Fig. 9B and Table 1). Concomitantly, the
homotypic aggregation of P3HR-1 cells induced by any of
three HDACIs or by phorbol ester was efficiently blocked
by NAC treatment (Fig. 10A). NAC treatment also com-
pletely blocked phorbol ester-induced homotypic aggre-
gation of the Ramos cell line (Fig. 10B). To confirm that
NF-B activation was responsible for the observed
ICAM-1 up-regulation, we took advantage of a super-
repressor IB, which contains point mutations altering
residues Ser32 and Ser36 to Ala, rendering IB resistant
to ubiquitination-dependent proteosomal degradation,
and thus ultimately inhibiting NF-B activation (DiDonato
et al., 1996). Ectopic expression of this super-repressor
IB inhibited HDACI-induced ICAM-1 expression by
40%, comparable to the suppression induced by domi-
nant-negative LMP-1AAAG expression (Fig. 11A and Table
1). To verify the activity of the dominant-negative IB
vector, a luciferase reporter construct with endothelial
FIG. 7. Nuclear runoff analysis of EBV LMP-1 transcripts in HDACI-
treated cells. 1  108 P3HR-1 cells were treated with 2.5 mM butyrate,
100 ng TSA/ml, or 20 ng PMA/ml, or left untreated for 24 h. Nuclei
isolated from the cells were used to prepare [32P]UTP-labeled runoff
transcripts, as described under Materials and Methods. Equivalent
cpm of radioactive transcripts were exhaustively hybridized with filters
containing 0.5 g of immobilized pGEM, -actin, EBV thymidine kinase
(TK), and EBV LMP-1 cDNAs. The filters were then washed and RNase-
treated prior to being exposed to film. A 72 h autoradiographic expo-
sure is shown. Quantitation was carried out by laser densitometry.
FIG. 8. Effect of ectopic expression of a dominant-negative LMP-1AAAG on HDACI-induced ICAM-1 up-regulation. (A) 1  107 P3HR-1 cells were
cotransfected with 10 g of E-GFP and 20 g of dominant-negative LMP-1 expression vector, or empty expression vector (as a control). After a 24 h
incubation, butyrate was added to 2.5 mM and the transfectants were incubated for another 24 h. Cells were harvested and surface-stained with a
human ICAM-1-specific mAb and a PE-conjugated goat anti-murine IgG (Beckman Coulter). The strongly GFP-positive subpopulation was gated on
and analyzed in the FL2 channel. See Table 1 for quantitation and comparison of mean fluorescence indices (m.f.i.). (B) The pICAM-1p-luc reporter
constructs designated BglII and NheI were cotransfected into the P3HR-1 cell line with expression vectors for LMP-1, DN-LMP-1, or LMP-1 
DN-LMP-1 (at a fourfold molar excess of LMP-1). A total of 10 g DNA per transfection was used and pGL3-Basic vector was used as a negative
control. Luciferase reporter activity was measured and expressed as specific activity (U/mg protein).
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cell-leukocyte adhesion molecule (ELAM) promoter con-
taining three NF-B binding sites was used (Schindler
and Baichwal, 1994). Phorbol ester induces ICAM-1 ex-
pression through NF-B activation (Mu¨ller et al., 1995),
and cotransfection of the super-repressor IB mutant
efficiently suppressed PMA-induced ELAM-luciferase
activity (Fig. 11B). Interestingly, ectopic expression of the
dominant-negative IB also suppressed the basal level
of ICAM-1 expression, suggesting that the NF-B signal-
ing pathway mediates basal ICAM-1 expression in the
P3HR-1 line. Thus, NF-B activation through latent LMP-1
expression appears necessary for maximal ICAM-1 up-
regulation and homotypic aggregation induced by HDA-
CIs or phorbol esters.
DISCUSSION
HDACIs are potent reactivators of lytic EBV gene ex-
pression, through the induction of EBV immediate-early
gene products Zta and Rta, presumably via viral promoter
activation by histone acetylation (Jenkins et al., 2000). In
a number of HDACI-responsive promoters, the HDAC is
recruited to the transcriptional machinery through bind-
ing to other transcriptional factors, whereupon it
deacetylates histones H3 and H4 and ultimately re-
presses gene transcription through remodeling of chro-
matin structure (Hassig and Schreiber, 1997; Marks et al.,
2000; Pazin and Kadonaga, 1997). Inhibitors of histone
deacetylase modulate the local acetylation status and
ultimately derepress gene transcription. Precisely how
HDAC inhibition induces transcription of the immediate-
early genes of EBV, and whether this is a direct effect on
their promoters, is not yet known, although new protein
synthesis is not required. Once the immediate-early EBV
transactivators Zta and Rta are induced, the complete
lytic cycle can be initiated, depending upon the cell type
studied (Cayrol and Flemington, 1996; Ragoczy and
Miller, 1999; Ring, 1994). The EBV-reactivation efficiency
of HDACIs alone is not as high as that of butyrate plus
phorbol ester treatment, and treatment with both phorbol
ester and butyrate has been a traditional pharmacologic
stimulus for reactivation of the lytic process in the
P3HR-1 line (Kawanishi and Ito, 1980; Miller, 1989; Weigel
and Miller, 1983). Interestingly, in our studies, we could
not detect any significant level of EBV reactivation with
phorbol ester treatment alone in a number of cell lines,
including Akata, Daudi, IB4, Namalwa, and P3HR-1 (un-
published data, Park and Faller). Concordantly, we failed
to find significant levels of Zta or Rta transcripts in the
P3HR-1 line by RNA blot analysis at 48 h of phorbol ester
treatment. Yet, all of the HDACIs studied herein induced
TABLE 1
Summary of Relative Inhibition of ICAM-1 Expression by Various Treatments
Untreated Treatment Fold change % Inhibitiona
DN-LMP1AAAG transfection
Butyrate-treated
Control 192.82b 537.61 2.8 —
DN-LMP1 179.43 368.47 2.0 41
NAC treatment (P3HR-1)
Butyrate-treated
Control 80.58 437.14 5.4
NAC 69.78 173.09 2.5 67
TSA-treated
Control — 228.76 2.8
NAC — 77.74 1.1 94
SHA-treated
Control — 222.67 2.8
NAC — 87.38 1.3 86
PMA-treated
Control — 194.56 2.4
NAC — 67.93 1.0 100
NAC treatment (Ramos)
PMA-treated
Control — 235.01 1.3 —
NAC — 129.80 0.7 100
Super-IB transfection
Butyrate-treated
Control 250.29 491.37 2.0 —
Super-IB 192.82 307.81 1.6 38
a See Materials and Methods for details.
b Calculated from the mean fluorescence indices (m.f.i.), as detailed under Materials and Methods.
DN, dominant-negative; NAC, N-acetyl-L-cysteine.
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EBV immediate-early gene expression as early as 6 h.
We confirmed that the EBV reactivation process induced
by HDACI extended to the induction of late, structural
genes by probing with the BALF4 fragment, which en-
codes the gp110 structural protein (unpublished data,
Park and Faller).
Treatment of P3HR-1 cells and other EBV-positive cell
lines, including Daudi and Akata, with HDACIs strongly
increased homotypic aggregation as early as 24 h after
exposure. Homotypic aggregation in EBV-positive cell
lines, and in particular the JY cell line, has been previ-
ously observed after phorbol ester treatment (Rothlein
and Springer, 1986). Phorbol ester-induced aggregation
of JY cells appears to be mediated by the interaction of
LFA-1 and ICAM-1. We found that the CD18-specific mAb
TS1/18 blocked the observed HDACI-induced homotypic
aggregation in the P3HR-1 line, as well as phorbol ester-
induced aggregation of the JY line. CD18 is a common
subunit for LFA-1, Mac-1/CR4, and p150/95 (Sanchez-
Madrid et al., 1983) and both LFA-1 and Mac-1 are known
to bind to the ICAM family members. HDACI treatment
significantly up-regulated ICAM-1 expression in the
P3HR-1 line, while having minimal or no effect on the
expression of LFA-1 or ICAM-2. In contrast, HDACI treat-
ment of the Ramos line caused almost no change in
surface expression of LFA-1 or ICAM-1/-2/-3 above basal
levels. Interestingly, phorbol ester treatment induced
strong homotypic aggregation in the Ramos line, despite
the lack of LFA-1 expression or ICAM induction. There
are two recognized mechanisms of activating adhesion
through LFA-1 (Binnerts and van Kooyk, 1999). One is by
increasing the level of LFA-1 protein expression, while
the second means of activation is via an induced con-
formational change of the LFA-1 molecule, resulting in
increased affinity for ICAM molecules, and this latter
mechanism is thought to be the one commonly initiated
by phorbol esters. The P3HR-1 line expresses LFA-1 and
ICAM-1/-2 antigens at moderate levels under control
conditions, and both HDAC inhibition and phorbol ester
treatments further induce ICAM-1 antigen levels. Even
partially blocking the up-regulation of ICAM-1 by any of a
number of modalities was sufficient to inhibit aggrega-
tion. In contrast, phorbol ester treatment induced homo-
typic aggregation of Ramos cells without increasing
LFA-1 or ICAM-1/-2/-3 levels. Taken together, these data
suggest that HDACI-induced and phorbol ester-induced
homotypic aggregation differ mechanistically from each
other, and that up-regulation of ICAM-1 expression may
FIG. 9. Effect of N-acetyl-L-cysteine on HDACI or phorbol ester induced ICAM-1 up-regulation. 5  106 P3HR-1 cells (A) or Ramos cells (B) were
treated with various HDACIs (butyrate, TSA, or SHA) or PMA, with or without NAC (at 20 mM), for 18 h and harvested, surface-stained, and analyzed
for ICAM-1 expression. The (control) profiles depicted by the thin lines were generated from cells treated with second antibody alone. See Table 1
for quantitation and comparison of mean fluorescence indices (m.f.i.).
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be the major mechanism underlying HDACI-induced ag-
gregation in the P3HR-1 line. However, the finding that
anti-CD18 mAb (TS1/18) treatment blocked the adhesion
induced either by any of three distinct HDACI, or by
phorbol ester, indicates that LFA-1 and its ICAM ligand(s)
are providing the major contribution under all of these
experimental conditions.
Attempts to confirm that ICAM-1 was the ICAM family
member mediating the homotypic adhesion of EBV-pos-
itive B cell lines induced by HDAC inhibition were com-
plicated by the technical inability to carry out blocking
studies with ICAM-1-specific antibodies in these EBV-
transformed B cell lines. Two lines of indirect evidence
strongly support the critical role of ICAM-1, however. The
first is that only ICAM-1 levels were induced by HDAC
inhibitors, with levels of ICAM-2 unchanged in the
P3HR-1 cell line, and no ICAM-3 expression was de-
tected. The second line of evidence is that suppression
of ICAM-1 induction, using N-acetyl-cysteine, dn-LMP-1,
or proteolysis-resistant IB, also abrogated homotypic
aggregation.
We unexpectedly found that the latent isoform of
LMP-1 was induced by HDACI treatment. LMP-1 is gen-
erally considered to be a latent gene product and is
involved in immortalization of B lymphocytes. LMP-1
shares common properties with the TNF-receptor
(TNF-R) family of proteins. Ectopic expression of LMP-1
constitutively activates the NF-B pathway through its
CTAR-1 and -2 domains. It has been previously reported
that treatment of the Daudi cell line with butyrate, or
superinfection with an EBV-containing supernatant to
initiate the EBV reactivation process, resulted in induc-
tion of both latent and lytic LMP-1 (Contreras-Salazar et
al., 1990), but it also has been reported that the lytic
LMP-1 is not expressed in the P3HR-1 line after reacti-
vation stimuli (Sjo¨blom-Halle´n et al., 1999). Because both
the Daudi and the P3HR-1 cell lines have deletions in the
EBNA-2/-LP region, a region thought to be essential for
viral induction of lytic LMP-1, we first speculated that the
observed LMP-1 transcript expression might represent
the lytic isoform of LMP-1. Somewhat surprisingly, how-
ever, both RT-PCR and immunoblot analyses demon-
FIG. 10. Effect of N-acetyl-L-cysteine on HDACI and phorbol ester induced homotypic aggregation. 5 106 P3HR-1 cells (A) or Ramos cells (B) were
left untreated or treated with various HDACIs (butyrate, TSA, or SHA), with or without NAC (at 20 mM), for 18 h, harvested, and resuspended at 106
cells/ml. One hundred microliters of the cell suspensions was added to individual wells of a 96-well plate. The cells were incubated for 18 h, examined
under phase contrast microscopy, and representative fields were photographed.
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strated that it was the latent isoform of LMP-1 that was
induced by HDACI treatment. Nuclear runoff analyses
indicated that HDACI-induced LMP-1 mRNA expression
is largely attributable to effects at the transcriptional
level. In parallel studies, we have also observed induc-
tion of the latent isoform of LMP-1 in Daudi and JY cell
lines after HDAC inhibition (unpublished data, Park and
Faller).
Using a dominant-negative form of LMP-1 (LMP-1AAAG),
we showed that observed ICAM-1 up-regulation induced
by HDACI was mediated, at least in part, by latent LMP-1.
The dominant-negative LMP-1 harbors four point muta-
tions that abrogate the functions of CTAR-1 and -2, re-
sulting in failure to activate NF-B. NF-B activation by
LMP-1 was shown to mediate ICAM-1 up-regulation in
EBV-positive cell lines (Huen et al., 1995). Transfection of
the dominant-negative LMP-1, to inhibit HDACI-induced
endogenous LMP-1 activities, suppressed ICAM-1 up-
regulation by up to 30%, in a dose-dependent fashion.
This less-than-complete inhibition of LMP-1 induction is
consistent with the recent findings that ICAM-1 up-reg-
ulation by LMP-1 may not be exclusively through NF-B
activation (Liljeholm et al., 1998; Mehl et al., 2001). A
pharmacological inhibitor of NF-B activation (N-acetyl-
L-cysteine) was used to demonstrate the necessity of
NF-B activation for the induction of ICAM-1 up-regula-
tion by HDACI-induced LMP-1. N-acetyl-L-cysteine effi-
ciently inhibited ICAM-1 up-regulation by HDACI and by
phorbol ester treatment in the P3HR-1 line, by up to 60%,
and also blocked phorbol ester-induced ICAM-1 up-reg-
ulation in the Ramos line. Consistent with our hypothe-
sis, this inhibitor concurrently completely blocked homo-
typic aggregation in the HDACI- or phorbol ester-treated
P3HR-1 line and in the phorbol ester-treated Ramos line.
The ectopic expression of super-repressor IB also
efficiently inhibited HDACI-induced ICAM-1 expression
in the P3HR-1 line. Thus, NF-B activation may be a
common mediator in both HDACI- and phorbol ester-
induced ICAM-1 up-regulation and results in homotypic
aggregation in EBV-positive B cell lines, as well as ho-
motypic aggregation in EBV-negative cell lines (e.g.,
Ramos), which is not mediated by ICAM-1 induction.
Because HDAC inhibitors are currently being employed
in clinical trials for the treatment of EBV-associated ma-
lignancies (Faller et al., 2001; Mentzer et al., 1998, 2001),
it is of interest to speculate upon the ramifications of
ICAM-1 induction on EBV-infected cells by these agents.
Homotypic aggregation itself likely has little or no coun-
terpart in vivo. In contrast, induction of ICAM-1 expres-
sion might either hinder or facilitate tumor spread. For
example, up-regulation of adhesion molecules on lym-
phoma cells has been implicated in facilitating their
spread in the host (Anastassiou et al., 2000). In contrast,
high levels of expression of ICAM-1 might instead facil-
itate immune destruction of the infected tumor cells by
cytotoxic T lymphocytes (Gwin et al., 1996; Huang et al.,
2000; Luo et al., 1999), as LFA-1/ICAM-1 interactions
provide one of the first steps in the recognition and lytic
cascade of CTLs with target cells. The ultimate conse-
quences in vivo may reflect a combination of these two
adverse outcomes.
In this article, we describe a new consequence of
FIG. 11. Effect of super-repressor IB on HDACI-induced ICAM-1
up-regulation. (A) 1  107 P3HR-1 cells were cotransfected with 10 g
E-GFP and 20 g of super repressor IB expression vector, or empty
expression vector (as a control). After 24 h incubation, butyrate was
added to 2.5 mM and the transfectants were incubated for another 24 h.
Cells were harvested and surface-stained with a human ICAM-1-spe-
cific mAb and a PE-conjugated goat anti-murine IgG (Beckman
Coulter). The strongly expressing GFP-positive subpopulation was
gated on and analyzed in the FL2 channel. The (control) profiles
depicted by the thin lines were generated from cells treated with
second antibody alone. See Table 1 for quantitation and comparison of
mean fluorescence indices (m.f.i.). (B) Same set of experiment was
done with ELAM promoter reporter construct. 1  107 P3HR-1 cells
were cotransfected with 10 g of pELAMp-luc and 20 g of super-
repressor IB expression vector, or empty expression vector (as a
control). After 24 h incubation, phorbol ester (PMA) was added to 20
ng/ml and the transfectants were incubated for another 24 h. Cells
were harvested and total protein lysate was prepared. Specific activity
was calculated based on total milligram protein used. pGEM and
pSV2-luc constructs were used as negative and positive transfection
control, respectively.
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HDAC inhibition, resulting in the induction of latent
LMP-1 during the EBV reactivation process. The HDACI-
induced latent LMP-1 mediates ICAM-1 up-regulation,
and thus homotypic aggregation, through NF-B activa-
tion. The mechanism of LMP-1 regulation by HDAC inhi-
bition is still not elucidated. LMP-1 expression by HDACI
treatment is regulated, at least in part, at the transcrip-
tional level. The viral product EBNA-2 is known to regu-
late LMP-1 gene expression through binding to putative
RBP-J elements in the LMP-1 promoter (Strobl et al.,
1997). The P3HR-1 and Daudi cell lines are deficient in
EBNA-2, however, because of a deletion in the EBV
episome. It has recently been proposed that activated
Notch protein can functionally substitute EBNA-2 in
terms of EBNA-2-dependent cellular and viral gene ex-
pression, including that of LMP-1 (Cotter et al., 2000;
Gordadze et al., 2001; Ho¨felmayr et al., 1999, 2001; Ku-
sano and Raab-Traub, 2001; Sakai et al., 1998; Strobl et
al., 2000). It is therefore possible, but unproven, that
HDAC inhibition might activate endogenous Notch pro-
tein(s), which could then transcriptionally activate LMP-1.
LMP-1 gene might be activated by HDACI treatment
through other EBNA-2-independent, ATF/CRE-dependent
pathways (Sjo¨blom et al., 1998). Takacs et al. recently
reported that B cell lines expressing LMP-1 carried EBV
genomes with an unmethylated or hypomethylated
LMP-1 promoter (LRS). They postulated that hypermeth-
ylation in or near the LMP-1 promoter in LMP-1-negative
cells might comprise an indirect mechanism for silencing
of the LMP-1 promoter, via methylcytosine-binding pro-
teins (Takacs et al., 2001). Butyrate and related short-
chain fatty acids have been reported to alter the meth-
ylation status of genomic DNA (Cosgrove and Cox, 1990;
Boffa et al., 1994), making this a plausible mechanism for
derepression of LMP-1 transcription. However, structur-
ally unrelated HDAC inhibitors, such as the hydroxamic
acids, also induced LMP-1 in our studies, and these
compounds are not known to affect DNA methylases.
Thus, the future determination of the precise mecha-
nism and functional consequences of latent LMP-1 ex-
pression during the HDACI-induced EBV reactivation
process may delineate a new role for LMP-1 in EBV-
associated human pathology.
MATERIALS AND METHODS
Cell lines and reagents
The Akata, Daudi, JY, Namalwa, and P3HR-1 cell lines
are EBV-positive B cell lines established from BL. IB4 B
lymphoblastoid cell line was generated by in vitro EBV
infection. Ramos is an EBV-negative B cell line, also
established from a BL. All cell lines were grown in sus-
pension in RPMI 1640 plus 10% FCS supplemented with
2 mM glutamine, 200 U penicillin/ml, and 200 U strepto-
mycin/ml and were maintained at 37°C in a humidified
atmosphere with 5% CO2. The HDACIs used in these
studies included butyrate at 1 or 2.5 mM (Sigma Chem-
ical Co., St. Louis, MO), TSA at 100 ng/ml (WAKO Chem-
icals USA Inc., Richmond, VA), and suberoylhydroxamic
acid (SHA) at 60 M (Aldrich Chemical Co., Milwaukee,
WI). Phorbol ester (phorbol-12-myristate-13-acetate, PMA
or TPA) (Sigma) was used at a concentration of 20 ng/ml.
NAC (Calbiochem-Novabiochem Co., San Diego, CA), a
reducing agent and inhibitor of NF-B activation, was
used at a final concentration of 20 mM.
Cell-surface labeling and flow cytometry
For antibody cell-surface labeling analyses, mAbs di-
rected against CD11a (-chain of LFA-1), CD18 (-chain
of LFA-1), CD54 (ICAM-1), CD102 (ICAM-2), and CD50
(ICAM-3) were purchased from Beckman Coulter (Miami,
FL). Treated or untreated cells were harvested and wash
twice with ice-cold 1 Earle’s balanced salt solution plus
0.5% bovine serum albumin (BSA) (EBSS/BSA) solution.
The cells were resuspended in 2 ml EBSS/BSA solution
and centrifuged again for 5 min at 1000 rpm. The cells
were resuspended in 50 l of murine anti-human primary
antibody (Ab) (1:50 dilution) in EBSS/BSA solution. The
suspensions were mixed gently for 45 min at 4°C, then
washed twice with EBSS/BSA solution, and resuspended
again in 50 l of sheep FITC-conjugated anti-mouse
secondary Ab (Amersham Pharmacia Biotech., Bucking-
hamshire, U.K.) (1:50 dilution) in EBSS/BSA solution. The
mix was shaken for 45 min at 4°C, then washed twice
with EBSS/BSA solution, resuspended in 200 l EBSS/BSA
solution plus 200 l 2% paraformaldehyde, and stored in
the dark at 4°C. The stained cells were analyzed using
CellQuest program at FL1 channel of a FACScan (Becton–
Dickinson Co., San Jose, CA) within 2 days.
Homotypic aggregation blocking assay
Cells were treated with butyrate (2.5 or 1 mM), tricho-
statin A (TSA, 100 ng/ml), suberoylhydroxamic acid (SHA,
60 M), or phorbol ester (20 ng/ml) for 24 h, and then
harvested and resuspended in complete RPMI 1640 me-
dium at 106 cells/ml. TS1/18 mAb, directed against CD18
(the common -chain of LFA-1), or W6/32 mAb, directed
against a framework antigen on HLA as an isotype con-
trol, was used to test for effects on homotypic aggrega-
tion. To each 96-well, 50 l of cell suspension and 100 l
of TS1/18 mAb or 100 l of W6/32 mAb culture superna-
tant was added. After another overnight incubation, each
well was evaluated for homotypic aggregation by micros-
copy.
Immunoblot analysis
Treated cells were harvested and washed twice with
PBS. To the pellet, 500 l of cold lysis buffer (1 PBS, 1%
NP-40, 0.02% sodium azide, protease inhibitor cocktail
tablets (Roche Diagnostics GmbH, Mannheim, Germany)
per 10 ml lysis buffer) for 1  107 cells was added, and
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the suspension was transferred to a microtube. The
tubes were rocked for 15 min at 4°C and were centri-
fuged for 10 min. Total protein concentration was mea-
sured by Bio-Rad Protein Assay solution (Hercules, CA).
A total of 30 g denatured protein was loaded in each
lane for separation by SDS–PAGE. The proteins were
transferred to a nitrocellulose membrane using sub-
merged tank system, and then the membrane was
blocked with 10% FCS, 1% BSA, and 5% nonfat dry milk in
PBST (0.5% Tween 20 in 1 PBS) solution overnight at
4°C. The membrane was washed three times with wash-
ing buffer (1% BSA, 5% nonfat dry milk in PBST) and
probed with the primary antibody at an appropriate dilu-
tion in washing buffer for 1 h, washed three times with
washing buffer, and then incubated for 1 h with a 1/5000
dilution of peroxidase-linked goat anti-rabbit IgG or of
peroxidase-linked sheep anti-mouse IgG (Amersham
Pharmacia Biotech.) at room temperature, washed with
washing buffer, and developed using ECL Plus Western
blotting detection reagents (Amersham Pharmacia Bio-
tech). Rabbit serum raised against whole EBV TK protein
was used as the primary antibody (Dr. Joyce Fingeroth,
Harvard Institute of Medicine, MA). The CS1-4 mAb
(DAKO Co., Glostrup, Denmark) and G-5 mAb (Santa Cruz
Biotech., Santa Cruz, CA) (both at 0.5 g/ml) were used
to detect EBV LMP-1 and human ICAM-1, respectively.
Luciferase reporter assays
Reporter plasmids pELAMp-luc (Dr. Matthew Fenton,
Boston University School of Medicine, MA) (Schindler
and Baichwal, 1994), which contains functional NF-B
promoter elements, and pSSB-luc (Dr. Shih-Tung Liu,
Chang-Gung University, Taiwan) (Hung and Liu, 1999),
containing Zta/Rta-responsive elements, were used to
assay NF-B activity and Zta/Rta activity, respectively.
The ICAM-1 reporter plasmids, pICAM-1p-luc (Mehl et
al., 2001), containing two NF-B sites (1150 bp, BglII
construct) or only a TATA box (60 bp, NheI construct)
(the generous gifts of Dr. Tomas Parks, Cellegy Pharma-
ceuticals, South San Francisco, CA), were used to assay
LMP-1-mediated ICAM-1 expression. P3HR-1 cells were
cotransfected with the appropriate promoter-luciferase
vectors plus super-repressor IB or LMP-1 expression
vectors. Transfectants were treated with butyrate (2.5
mM) on Day 1 and total cell lysates were prepared on
Day 2 after transfection. The luciferase assays system
from Promega (Madison, WI) was used and the assays
were performed according to the manufacturer’s instruc-
tions. Total protein concentration was measured by Bio-
Rad Protein Assay. Specific activity was calculated
based upon quantity of protein (in milligrams) used.
Nuclear-runoff transcript analysis
Nuclei were prepared from approximately 108 actively
growing P3HR-1 line (treated or untreated), using a mod-
ification of the technique previously described (McKnight
and Palmiter, 1979; Vaziri and Faller, 1995). Briefly, cells
were lysed in a buffer containing 50 mM Tris (pH 7.5), 100
mM KCl, 5 mM MgCl2, 15% glycerol, 1 mM DTT, and 0.2%
NP-40, and nuclei were purified by centrifugation at 1000
rpm for 5 min. Nuclei were resuspended in 200 l of cold
lysis buffer without NP-40 and incubated with 25 l
[32P]UTP (250 Ci), 55 l 5 transcription buffer (100 mM
Tris (pH 8.0), 500 mM KCl, 25 mMMgCl2, 10 mM DTT, 500
M of each ATP, CTP, and GTP, and 12 M UTP), and 5
l RNAsin at 26°C for 30 min. The nuclei were spun out
gently and resuspended in 200 l 1 transcription
buffer, and then 5 l yeast carrier RNA stock (10 mg/ml)
and 25 l RNase-free DNase stock (1 mg/ml) were
added to the nuclei, and the mix was incubated at 37°C
for 15 min. Then, 25 l 10% SDS stock and 20 l protease
K stock (10 mg/ml) were added and the mixture incu-
bated further at 37°C for 15 min. The nucleic acids were
extracted with hot phenol/chloroform at 60°C, precipi-
tated in EtOH, washed once with 70% EtOH, and dried.
Total cpm was measured and 10–20  106 cpm was
used in 1 ml hybridization buffer. An amount of 0.5 g of
DNA specific for pGEM, -actin, EBV TK (pET-TKB1B, gift
of Dr. Yang, National Taiwan University, Taiwan), and EBV
LMP-1 (pUC-Ly9, gift of Dr. Wang, Brigham & Women’s
Hospital, Boston) were denatured, neutralized, spotted
onto nitrocellulose by using a dot-blot apparatus, and
fixed by baking in vacuo. Prehybridization and hybridiza-
tion were carried out in 40% formamide, 4 SSC, 5 mM
EDTA, 0.4% SDS in the presence of 1 Denhardt’s solu-
tion and 100 g/ml yeast carrier RNA at 40°C. For ex-
haustive hybridization, labeled RNA was added to 1 ml
hybridization buffer, and incubation at 40°C was carried
out for 72 h. High stringency washes of the filters were
as described (Wilson et al., 1987). The filters were ex-
posed for 3–4 days at 80°C.
Reverse transcriptase-polymerase chain reaction
(RT-PCR)
Twenty micrograms of total cellular RNA was incu-
bated overnight with RQ1 RNase-free DNase (Promega).
The mixture was subjected to phenol/chloroform extrac-
tion and EtOH precipitation. Five micrograms of the
DNase-treated RNA sample was used for each reverse
transcriptase reaction, using the SuperScript First-Strand
Synthesis System (Invitrogen, Carlsbad, CA). For latent
LMP-1 detection, sense (5-GAACACGACCTTGAGAGG-
GGCCCACCGGGC-3) and antisense (5-CTGCCAGATG-
GTGGCACCAAGTCGCCAGAG-3) primers were chosen
from the first and third exons of latent LMP-1, which can
differentiate latent from lytic LMP-1 transcripts (Hudson
et al., 1985). A -actin primer set (Promega) was used for
an internal RT-PCR control.
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RNA blot analysis
Total cellular RNA was prepared by the guanidine
thiocyanate solution method or by the Trizol reagent
method (Invitrogen). RNA was separated by 1% formal-
dehyde-agarose gel electrophoresis, running overnight
at 30 mA. A total of 20 g of RNA was loaded in each
lane. The picture was taken from the gel for equal load-
ing control after overnight run. Separated RNA was de-
natured by washing with 50 mM NaOH/10 mM NaCl
solution and neutralized with 0.1 M Tris (pH 7.5) for 45
min each. The RNA was transferred to a nitrocellulose
membrane in 20 SSC solution. Then the membrane
was baked for 2 h at 80°C in vacuo, prehybridized for 4 h,
and probed with specific primers at 42°C for overnight.
The DNA probes were 32P-labeled by the random primer
method. The membrane was washed twice with low
stringency buffer (5 SSC/0.1% Sarcosyl) for a total of 1 h
and then twice with medium stringency buffer (2 SSC/
0.1% Sarcosyl) for a total of 1 h, and then exposed to X-ray
film at 80°C.
Transfections
pSG5-LMP-1 and dominant-negative LMP-1 (pSG5-
LMP-1AAAG) expression plasmids were generously pro-
vided by Dr. Martin Rowe (University of Wales College of
Medicine, U.K.). Zta (pBS[SVp/E]-Zta) and Rta (pRTS15)
expression vectors were provided by Dr. Rodriguez (Tu-
lane Cancer Center, LO) and Dr. Hayward (Johns Hop-
kins School of Medicine, MD), respectively. A super-
repressor IB (pRc/-actin-IBS32/36A) expression
vector was provided by Dr. Michael Karin (University of
California at San Diego, CA). For transient expression
assays, 1  107 cells from culture suspension were
cotransfected with each expression vector plus the
EGFP-C1 expression vector. Transient transfection was
carried out by electroporation, using a Bio-Rad Gene-
pulser II electroporator at 300 V and high capacitance
(950 F) at room temperature in 500 l RPMI medium
(Ning et al., 1995). After 5 min incubation at room tem-
perature, cells were reseeded into 5 ml fresh growth
medium and incubated further at 37°C in a 5% CO2
incubator. For analysis of ICAM-1 expression, the trans-
fectants were grown for 24 h, and HDAC inhibitors were
added to some samples and then further incubated for
another 24 h. The cells were harvested and cell-surface
labeling with antibody was performed as above. Phyco-
erythrin (PE)-conjugated goat anti-murine IgG (Beckman
Coulter) was used as a secondary antibody for cell-
surface staining. Normally, the transfection efficiencies
were less then 10% for Ramos and approximately 30% for
P3HR-1, as assessed by cotransfection with EGFP-C1
expression vector and flow cytometric analysis. Strongly
expressing GFP-positive cells were gated on and ana-
lyzed for ICAM-1 expression using the FL2 channel of a
FACScan (Becton–Dickinson Co.) within 2 days. The me-
dian fluorescence index was read from the FACScan
data and the % inhibition ratio was calculated as follows:
% Inhibition
 1 
Treated Index  Untreated Index]
Untreated Index
[Treated Control Index  Untreated Control Index]
Untreated Control Index

 100
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